Pelvic seromucinous borderline tumor 26 years after ovarian seromucinous borderline tumor managed with post-treatment estrogen replacement therapy

• A 56-year-old woman developed two seromucinous borderline tumors 26 years apart. • The second cyst was diagnosed as a seromucinous borderline tumor associated with pelvic endometriosis. • The first ovarian cancer was re-diagnosed as an ovarian seromucinous borderline tumor after a pathological sli...

Descripción completa

Detalles Bibliográficos
Autores principales: Uehara, Takashi, Yoshida, Hiroshi, Kato, Tomoyasu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7806793/
https://www.ncbi.nlm.nih.gov/pubmed/33490352
http://dx.doi.org/10.1016/j.gore.2020.100692
_version_ 1783636601119703040
author Uehara, Takashi
Yoshida, Hiroshi
Kato, Tomoyasu
author_facet Uehara, Takashi
Yoshida, Hiroshi
Kato, Tomoyasu
author_sort Uehara, Takashi
collection PubMed
description • A 56-year-old woman developed two seromucinous borderline tumors 26 years apart. • The second cyst was diagnosed as a seromucinous borderline tumor associated with pelvic endometriosis. • The first ovarian cancer was re-diagnosed as an ovarian seromucinous borderline tumor after a pathological slide review. • Seromucinous borderline tumors can re-occur several years after post-treatment estrogen replacement therapy. • Post-treatment estrogen replacement therapy for seromucinous borderline tumors should be provided carefully.
format Online
Article
Text
id pubmed-7806793
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-78067932021-01-22 Pelvic seromucinous borderline tumor 26 years after ovarian seromucinous borderline tumor managed with post-treatment estrogen replacement therapy Uehara, Takashi Yoshida, Hiroshi Kato, Tomoyasu Gynecol Oncol Rep Case Report • A 56-year-old woman developed two seromucinous borderline tumors 26 years apart. • The second cyst was diagnosed as a seromucinous borderline tumor associated with pelvic endometriosis. • The first ovarian cancer was re-diagnosed as an ovarian seromucinous borderline tumor after a pathological slide review. • Seromucinous borderline tumors can re-occur several years after post-treatment estrogen replacement therapy. • Post-treatment estrogen replacement therapy for seromucinous borderline tumors should be provided carefully. Elsevier 2020-12-28 /pmc/articles/PMC7806793/ /pubmed/33490352 http://dx.doi.org/10.1016/j.gore.2020.100692 Text en © 2020 The Author(s) http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Uehara, Takashi
Yoshida, Hiroshi
Kato, Tomoyasu
Pelvic seromucinous borderline tumor 26 years after ovarian seromucinous borderline tumor managed with post-treatment estrogen replacement therapy
title Pelvic seromucinous borderline tumor 26 years after ovarian seromucinous borderline tumor managed with post-treatment estrogen replacement therapy
title_full Pelvic seromucinous borderline tumor 26 years after ovarian seromucinous borderline tumor managed with post-treatment estrogen replacement therapy
title_fullStr Pelvic seromucinous borderline tumor 26 years after ovarian seromucinous borderline tumor managed with post-treatment estrogen replacement therapy
title_full_unstemmed Pelvic seromucinous borderline tumor 26 years after ovarian seromucinous borderline tumor managed with post-treatment estrogen replacement therapy
title_short Pelvic seromucinous borderline tumor 26 years after ovarian seromucinous borderline tumor managed with post-treatment estrogen replacement therapy
title_sort pelvic seromucinous borderline tumor 26 years after ovarian seromucinous borderline tumor managed with post-treatment estrogen replacement therapy
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7806793/
https://www.ncbi.nlm.nih.gov/pubmed/33490352
http://dx.doi.org/10.1016/j.gore.2020.100692
work_keys_str_mv AT ueharatakashi pelvicseromucinousborderlinetumor26yearsafterovarianseromucinousborderlinetumormanagedwithposttreatmentestrogenreplacementtherapy
AT yoshidahiroshi pelvicseromucinousborderlinetumor26yearsafterovarianseromucinousborderlinetumormanagedwithposttreatmentestrogenreplacementtherapy
AT katotomoyasu pelvicseromucinousborderlinetumor26yearsafterovarianseromucinousborderlinetumormanagedwithposttreatmentestrogenreplacementtherapy

Ejemplares similares